Virpax Pharmaceuticals, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

470

Shareholding (Dec 2024)

FII

0.33%

Held by 3 FIIs

DII

99.06%

Held by 1 DIIs

Promoter

0.00%

How big is Virpax Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Virpax Pharmaceuticals, Inc. has a market capitalization of 0.33 million, with net sales of 0.00 million and a net profit of -12.07 million over the last four quarters. The company reported shareholder's funds of -0.91 million and total assets of 1.56 million as of Dec 24.

What does Virpax Pharmaceuticals, Inc. do?

22-Jun-2025

Virpax Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $0.33 million. Key metrics include a debt-to-equity ratio of 1.51 and a return on equity of 1,206.72%.

Is Virpax Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of March 21, 2025, Virpax Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals from technical indicators, including mildly bullish MACD readings, bearish moving averages, and a significant year-to-date decline of -99.87%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.51

Return on Equity

1,206.72%

Price to Book

-0.01

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2024)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

70.73%

6 Months

-91.26%

1 Year

-99.79%

2 Years

-99.98%

3 Years

-97.47%

4 Years

-100.0%

5 Years

0.0%

Virpax Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Virpax Pharmaceuticals, Inc. technically bullish or bearish?

As of 21 March 2025, the technical trend for Virpax Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the weekly RSI shows no signal, and the monthly RSI is bullish, suggesting mixed signals. The daily moving averages are bearish, and both the weekly and monthly KST and Dow Theory indicators are bearish. The Bollinger Bands indicate a sideways trend on the weekly and mildly bearish on the monthly. In terms of performance, the stock has had a significant decline, with a year-to-date return of -99.87% compared to the S&P 500's 12.22%, and a one-year return of -99.94% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by bearish moving averages and Dow Theory, despite some positive momentum indicated by the MACD....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

6.86%

EBIT to Interest (avg)

-15.03

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.51

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.37%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.30

EV to EBIT

0.10

EV to EBITDA

0.10

EV to Capital Employed

0.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

497.77%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.62%)

Foreign Institutions

Held by 3 Foreign Institutions (0.33%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 26.09% vs -53.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-4.70",
          "chgp": "27.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-4.60",
          "chgp": "26.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.39% vs 29.95% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.10",
          "val2": "-16.90",
          "chgp": "28.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.10",
          "val2": "-15.20",
          "chgp": "20.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-4.70

27.66%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.40

-4.60

26.09%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is 26.09% vs -53.33% in Dec 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-12.10

-16.90

28.40%

Interest

0.10

0.00

Exceptional Items

0.00

1.20

-100.00%

Consolidate Net Profit

-12.10

-15.20

20.39%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.39% vs 29.95% in Dec 2023

All Annual Results

Company CV

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Virpax Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Virpax Pharmaceuticals, Inc.?

Watch in Real-Time

What does Virpax Pharmaceuticals, Inc. do?

Is Virpax Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Virpax Pharmaceuticals, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Virpax Pharmaceuticals, Inc.

Company Coordinates